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Metabolic syndrome (MetS) is a complex disorder combining hypertension, obesity, dyslipidemia, and insulin
resistance accompanying abnormal adipose deposition and function. MetS is associated with the development of
atherosclerotic cardiovascular disease, and contributes to the development of chronic kidney disease (CKD). A
close relationship between MetS and increased risk of developing renal damage has been established. Early diag-
nosis and treatment of MetS is essential in the forming of strategies to prevent CKD as a result of MetS. Several
findings have indicated that the activation of the intrarenal renin-angiotensin system (RAS) may play an impor-
tant role in the progression of MetS to CKD. Therefore, RAS blockade is a first-line therapeutic target for pre-
venting progression of MetS to CKD. The aim of this article is to provide an overview of the concept of MetS, and
to discuss the management of CKD in patients with MetS.
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Figure　1　Selected Japanese criteria for metabolic 
syndrome.
WC, waist circumference; TG, triglyceride; HDL, 
high-density lipoprotein cholesterol; BP, blood pres-
sure; FPG, fasting plasma glucose.















































































Figure　2　The mechanisms for incidence of microal-
buminuria in metabolic syndrome.
 (Modified from reference 20)
Obesity
Table　1　Histological analyses of the glomerular and tubulointerstitial damages in WKY/Izm rats and 




n 4 4 4 4
Glomerular damages
Glomerular sclerosis index 0.30±0.10 1.15±0.08＊ 1.10±0.07 0.50±0.12#†
Desmin staining index 1.20±0.09 3.10±0.07＊ 2.80±0.09 1.75±0.10＊#†
PCNA-positive cells per glomerulus 0.40±0.11 2.70±0.10＊ 2.35±0.11 0.95±0.14＊#†
Tubulointerstitial damages
Tubulointerstitial fibrosis index 0.20±0.09 1.40±0.11＊ 1.10±0.07＊ 0.70±0.11＊#†
Type IV collagen staining index 1.25±0.10 3.15±0.13＊ 2.70±0.10＊ 1.40±0.11#†
PCNA-positive cells per tubulointerstitial area 1.40±0.11 5.15±0.15＊ 4.70±0.16＊ 1.51±0.12#†
ARB, angiotensin II receptor blocker; PAS, periodic acid-shiff; PCNA, proliferating cell nuclear antigen.
Glomerular sclerosis index and desmin staining index were estimated semiquantitatively by scoring as 0-4 or 1-4 
degrees for PAS staining and desmin immunostaining, respectively.
Tubulointerstitial fibrosis index and Type IV collagen staining index were estimated semiquantitatively by scor-
ing as 0-4 or 1-4 degrees for Azan staining and Type IV collagen immunostaining, respectively. Data are ex-
pressed as the mean±s.e.
＊p＜0.05 vs. WKY/Izm.
#p＜0.05 vs. vehicle-treated SHR/NDmcr-cp group.
†p＜0.05 vs. hydralazine group.
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